1.Regulation of B cell activating factor (BAFF) receptor expression by NF-kappaB signaling in rheumatoid arthritis B cells.
Yun Ju WOO ; Bo Young YOON ; Joo Yeon JHUN ; Hye Jwa OH ; Sewon MIN ; Mi La CHO ; Sung Hwan PARK ; Ho Youn KIM ; Jun Ki MIN
Experimental & Molecular Medicine 2011;43(6):350-357
B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). High levels of B cell activating factor (BAFF) are detected in autoimmune diseases. BAFF and BAFF receptor (BAFF-R) are expressed in B and T cells of RA synovium. The study was undertaken to identify the NF-kappaB signal pathway involved in the induction of BAFF-R in human B cells. Immunohistochemical staining of NF-kappaB p65, NF-kappaB p50, BAFF, and BAFF-R was performed on sections of synovium from severe and mild RA and osteoarthritis (OA) patients. Peripheral blood mononuclear cells (PBMCs) were isolated from control and RA patients and B cells were isolated from controls. BAFF-R was analyzed by flow cytometry, realtime PCR and confocal staining after treatment with NF-kappaB inhibitors. NF-kappaB p65, NF-kappaB p50, BAFF, and BAFF-R were highly expressed in severe RA synovium relative to mild RA synovium or OA synovium. BAFF-R expression was reduced by NF-kappaB inhibitors in PBMCs and B cells from normal controls. We also showed reduction in expression of BAFF-R via inhibition of the NF-kappaB pathway in PBMCs of RA patients. BAFF/BAFF-R signaling is an important mechanism of pathogenesis in RA and that BAFF-R reduction by NF-kappaB blocking therapy is another choice for controlling B cells in autoimmune diseases such as RA.
Arthritis, Rheumatoid/genetics/*metabolism/pathology/physiopathology
;
B-Cell Activating Factor/genetics/metabolism
;
B-Cell Activation Factor Receptor/genetics/*metabolism
;
B-Lymphocytes/*drug effects/immunology/metabolism/pathology
;
Cell Separation
;
Cells, Cultured
;
Disease Progression
;
Enzyme Inhibitors/pharmacology
;
Flow Cytometry
;
Gene Expression Regulation/immunology
;
Humans
;
Immunohistochemistry
;
NF-kappa B/*metabolism
;
Signal Transduction/immunology
;
Synovial Membrane/*pathology
;
T-Lymphocytes/drug effects/immunology/metabolism/pathology
;
Transcriptional Activation/drug effects
2.The OPG/RANKL/RANK system and bone resorptive disease.
Ji-Zhong LIU ; Zong-Ling JI ; Su-Min CHEN
Chinese Journal of Biotechnology 2003;19(6):655-660
The OPG/RANKL/RANK system plays an important role in osteoclastogenesis and represents a great progress in bone biology. RANKL, which expresses on the surface of osteoblast/stromal cells and activated T cells, binds to RANK on the osteoclastic precursors or mature osteoclasts, and promotes osteoclastogenesis and bone resorption. While osteoprotegerin (OPG), which is expressed by osteoblasts/stromal cells, strongly inhibits bone resorption by binding to its ligand RANKL and thereby blocks the interaction between BANKL and RANK. A number of cytokines and hormones exert their effects on bone metabolism by regulating the OPG/RANKL ratio in the bone marrow microenvironment. RANK is also expressed on mammary epithelial cells and RANKL expression in these cells is induced by pregnancy hormones, RANKL and RANK are essential for the formation of the lactating mammary gland and the transmission of maternal calcium to neonates in mammalian species. Modulation of these systems provides a unique opportunity to develop novel therapeutics to inhibit bone loss in osteoporosis, rheumatoid arthritis, and bone metastasis of cancer. Further research should be focused on the cooperation of OPG/RANKL/RANK system with other signal pathways and the interactions among bone remodeling, immune system and endocrinology system. Currently, the development of OPG analogues or compounds which may stimulate OPG expression is becoming an attractive industry which may be profitable to both patients and manufacturers.
Animals
;
Bone Resorption
;
immunology
;
metabolism
;
Humans
;
Osteoclasts
;
cytology
;
metabolism
;
pathology
;
Osteogenesis
;
drug effects
;
genetics
;
immunology
;
Osteoprotegerin
;
metabolism
;
physiology
;
RANK Ligand
;
metabolism
;
physiology
;
Receptor Activator of Nuclear Factor-kappa B
;
metabolism
;
pharmacology
;
physiology
;
T-Lymphocytes
;
drug effects
;
immunology
3.Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.
Sung Nam PARK ; Kyung Tae NOH ; Young Il JEONG ; In Duk JUNG ; Hyun Kyu KANG ; Gil Sun CHA ; Su Jung LEE ; Jong Keun SEO ; Dae Hwan KANG ; Tae Ho HWANG ; Eun Kyung LEE ; Byungsuk KWON ; Yeong Min PARK
Experimental & Molecular Medicine 2013;45(2):e8-
We evaluated the effectiveness of rhamnogalacturonan II (RG-II)-stimulated bone marrow-derived dendritic cells (BMDCs) vaccination on the induction of antitumor immunity in a mouse lymphoma model using EG7-lymphoma cells expressing ovalbumin (OVA). BMDCs treated with RG-II had an activated phenotype. RG-II induced interleukin (IL)-12, IL-1beta, tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) production during dendritic cell (DC) maturation. BMDCs stimulated with RG-II facilitate the proliferation of CD8+ T cells. Using BMDCs from the mice deficient in Toll-like receptors (TLRs), we revealed that RG-II activity is dependent on TLR4. RG-II showed a preventive effect of immunization with OVA-pulsed BMDCs against EG7 lymphoma. These results suggested that RG-II expedites the DC-based immune response through the TLR4 signaling pathway.
Acute-Phase Proteins/metabolism
;
Adaptor Proteins, Vesicular Transport/metabolism
;
Animals
;
Antigens, CD14/metabolism
;
Bone Marrow Cells/cytology/drug effects
;
CD8-Positive T-Lymphocytes/*immunology
;
Carrier Proteins/metabolism
;
Cell Differentiation/drug effects
;
Cell Nucleus/drug effects/metabolism
;
Cell Proliferation/drug effects
;
Cytokines/biosynthesis
;
Dendritic Cells/cytology/drug effects/enzymology/*immunology
;
Enzyme Activation/drug effects
;
Lymphocyte Activation/*drug effects
;
Membrane Glycoproteins/metabolism
;
Mice
;
Mice, Inbred C57BL
;
Mice, Knockout
;
Mitogen-Activated Protein Kinases/metabolism
;
Myeloid Differentiation Factor 88/metabolism
;
NF-kappa B/metabolism
;
Neoplasms/immunology/*pathology
;
Pectins/*pharmacology
;
Phenotype
;
Protein Transport/drug effects
;
Receptors, Chemokine/metabolism
;
Signal Transduction/drug effects
;
T-Lymphocytes, Cytotoxic/cytology/drug effects
;
Toll-Like Receptor 4/*agonists/metabolism
4.Protection of polysaccharide ATPS-2 from Armillariella tabescens on immunological liver injury in mice induced by BCG plus LPS.
Feng LI ; Ye-Shou SHEN ; Jin-Bao MA ; Gen-Hai ZHAO ; Xin-Qiang SHI ; Qiao-Yun ZHU
China Journal of Chinese Materia Medica 2007;32(24):2645-2648
<b>OBJECTIVEb>To observe the effect of polysaccharide ATPS-2 from Armillariella tabescens on the immunological liver injury in mice induced by BCG plus LPS.
<b>METHODb>BCG and LPS were adopted to establish BCG plus LPS liver injury model in mice. The content of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and NO, the activity of superoxide dismutase (SOD) and malondiadehyde (MDA) content of liver homogenate in mice were measured by colorimetric method. The content of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), on serum were measured by enzyme linked immunosorbent assay (ELISA) , and T- and B-lymphocyte proliferation were measured by MTT. Index of liver, spleen and thymus were calculated after treatment.
<b>RESULTb>Polysaccharide ATPS-2 from A. tabescens (25, 50, 100 mg x kg(-1)) could obviously reduce the high level of ALT, AST, NO and TNF-alpha, IL-1 on serum, inhibit the high level of MDA, increase the low activity of SOD in liver homogenate and enhance T-and B-lymphocyte proliferation, elevate the spleen, thymic index and decrease liver index of the mice to different extent.
<b>CONCLUSIONb>Polysaccharide ATPS-2 from A. tabescens had apparently protective effects in the immunological liver injury mice induced by BCG plus LPS.
Agaricales ; chemistry ; Alanine Transaminase ; blood ; Animals ; Aspartate Aminotransferases ; blood ; B-Lymphocytes ; cytology ; Cell Proliferation ; drug effects ; Chemical and Drug Induced Liver Injury ; Interleukin-1 ; blood ; Lipopolysaccharides ; Liver ; metabolism ; pathology ; Liver Diseases ; immunology ; metabolism ; pathology ; Male ; Malondialdehyde ; metabolism ; Mice ; Mycobacterium bovis ; Nitric Oxide ; blood ; Polysaccharides ; isolation & purification ; pharmacology ; Protective Agents ; isolation & purification ; pharmacology ; Random Allocation ; Superoxide Dismutase ; metabolism ; T-Lymphocytes ; cytology ; Tumor Necrosis Factor-alpha ; blood